Extracorporeal Membrane Oxygenation Market Research, 2035
The global extracorporeal membrane oxygenation market was valued at $527.5 million in 2023, and is projected to reach $952.2 million by 2035, growing at a CAGR of 5% from 2024 to 2035. The growth of the extracorporeal membrane oxygenation market is driven by rise in prevalence of respiratory and cardiac diseases and technological advancements in ECMO systems. For instance, according to the Centers for Disease Control and Prevention (CDC), about 25 million people in the U.S. had asthma. This increasing prevalence of respiratory disorders significantly contributes to rise in demand for ECMO products.
Key Takeaways
- On the basis of component, the oxygenator segment dominated the global extracorporeal membrane oxygenation market size in 2023 and is expected to register the highest CAGR during the forecast period.
- On the basis of modulation, the veno arterial segment dominated the global extracorporeal membrane oxygenation market share in 2023 and is anticipated to be the fastest-growing segment during the forecast period.
- On the basis of application, the respiratory disorders segment dominated the market in terms of revenue in 2023 and is expected to register the highest CAGR during the forecast period.
- On the basis of patient type, the adult segment dominated the market in terms of revenue in 2023 and is anticipated to be the fastest-growing segment during the forecast period.
- Region-wise, North America dominated the market in terms of revenue in 2023. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
Extracorporeal membrane oxygenation (ECMO) is an advanced life-support technique used to provide prolonged cardiac and respiratory support to patients whose heart and lungs are unable to function adequately on their own. It involves circulating the patient's blood outside the body through an artificial lung (membrane oxygenator) that adds oxygen and removes carbon dioxide, then returning it to the body.
Extracorporeal membrane oxygenation (ECMO) offers several key advantages in managing critical cardiac and respiratory failure. It provides temporary support for the heart and lungs, allowing these organs to rest and recover. ECMO improves oxygenation and carbon dioxide removal, stabilizes hemodynamics, and enhances survival chances in life-threatening conditions. It is especially beneficial during complex surgeries or for patients awaiting heart or lung transplants.
Market Dynamics
The extracorporeal membrane oxygenation market growth is driven by increase in prevalence of chronic and acute respiratory and cardiovascular diseases. Conditions such as chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), and heart failure have become more common due to aging population, sedentary lifestyles, and environmental factors. These diseases often lead to severe complications requiring advanced life-support systems. For example, a patient with severe ARDS who does not respond to mechanical ventilation may benefit from ECMO support to maintain adequate oxygenation, allowing the lungs time to heal. Thus, rise in prevalence respiratory disorders drives the market growth.
In addition, rise in technological advancements in ECMO devices is another major extracorporeal membrane oxygenation market growth driver. Innovations led to the development of more compact, efficient, and user-friendly ECMO systems, making them more accessible in various healthcare settings. For instance, portable ECMO machines are now used in emergency transport and smaller hospitals, broadening their clinical applications beyond large tertiary care centers. Improvements in oxygenators, pumps, and monitoring systems have enhanced the safety, performance, and reliability of ECMO therapy, encouraging its wider used.
Furthermore, rise in the number of surgical procedures requiring cardiopulmonary support, including heart and lung transplants, also fuels the extracorporeal membrane oxygenation market opportunity. ECMO is often used as a bridge to transplantation or during recovery from complex surgeries. In many cardiac surgery cases, patients may require ECMO to stabilize their condition post-operatively. As surgical volumes increase globally, the demand for supportive technologies like ECMO is expected to grow accordingly.
Moreover, the government initiatives and increase in healthcare funding have further strengthened the ECMO market. Several countries are investing in advanced critical care infrastructure, including the provision of ECMO systems in public hospitals. In Germany, for example, the introduction of a national web-based dashboard (ECMO-Dash) to monitor ECMO usage has improved transparency, resource allocation, and data-driven healthcare planning. Such initiatives enhance the visibility and integration of ECMO into national health systems.
In addition, ECMO is finding growing use in neonatal and pediatric care. Newborns with congenital heart defects or respiratory failure may require ECMO support when conventional interventions like mechanical ventilation are insufficient. As neonatal intensive care units (NICUs) become more advanced, the use of ECMO in neonates has expanded, contributing to segment-specific market growth. For instance, a newborn with persistent pulmonary hypertension may be placed on ECMO to stabilize oxygen levels until the condition improves.
However, high cost associated with ECMO systems, which includes not only the initial capital investment but also the ongoing maintenance and operation costs, may hinder the market growth. This makes it less accessible, particularly in low- and middle-income regions. In addition, ECMO procedures require highly skilled professionals and specialized healthcare settings, limiting their use to well-equipped medical centers thereby restricting the market growth. On the other hand, rises in technological advancements in ECMO systems such as compact, portable devices and user-friendly monitoring interfaces are improving accessibility and clinical outcomes, which provides an extracorporeal membrane oxygenation market opportunity,
Segmental Overview
The extracorporeal membrane oxygenation market analysis is segmented on the basis of component, modulation, application, patient type, and region. By component, the market is classified into controllers, pumps, oxygenator, cannula, and accessories. By modulation, the market is segmented into veno arterial, veno venous, and others. By application, the market is classified into cardiac diseases, respiratory disorders, extracorporeal cardiopulmonary resuscitation. By patient type, the market is segmented into neonates, pediatric, and adult.
Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, Russia, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, Thailand, Malaysia, Indonesia, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, UAE, Argentina, and the rest of LAMEA).
By Component
The oxygenator segment dominated the extracorporeal membrane oxygenation market share in 2023 and is expected to register the highest CAGR during the forecast period. This is attributed to its critical role in gas exchange during ECMO procedures. In addition, advancements in oxygenator technology have improved efficiency, biocompatibility, and durability which supports the segment growth. Their increased application in both veno venous and veno arterial ECMO further drive demand for oxygenators. Rising cases of respiratory failure and cardiac conditions also contributed to higher usage.
By Modulation
The veno arterial segment dominated the extracorporeal membrane oxygenation market size in 2023 and is expected to register the highest CAGR during the forecast period. This is attributed to its widespread application in managing cardiac and cardiopulmonary failure. This modality is extensively used in patients with life-threatening cardiac conditions, such as cardiogenic shock and cardiac arrest, where both heart and lung support are required. The increase in incidence of cardiovascular diseases, advancements in ECMO technology, and growing awareness among healthcare providers further contributed to the segment growth.
By Application
The respiratory disorders segment dominated the extracorporeal membrane oxygenation industry in 2023 and is expected to register the highest CAGR during the forecast period. This is attributed to rise in prevalence of severe respiratory conditions such as acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), and pneumonia, which require advanced life-support interventions thereby drives the demand for ECMO products. Increasing adoption of ECMO in intensive care units, coupled with improved patient outcomes and growing clinical evidence supporting its efficacy in respiratory failure, has further accelerated segment growth.
By Patient Type
The adult segment dominated the extracorporeal membrane oxygenation market share in terms of revenue in 2023 and is expected to register the highest CAGR during the forecast period. This is attributed to the increase in prevalence of cardiovascular and respiratory conditions among adults, enhanced adoption of advanced ECMO technologies in adult intensive care settings, and favorable reimbursement policies.
By Region
The extracorporeal membrane oxygenation industry is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America region dominated the market in terms of revenue in 2023. The growth in this region is attributed to its robust healthcare infrastructure, high adoption of advanced technologies, and favorable reimbursement policies. The region's strong focus on innovation and early adoption of ECMO systems further boosts the market growth in the region.
However, the Asia-Pacific is expected to grow at the highest rate during the extracorporeal membrane oxygenation market forecast period. This is attributed to growing healthcare infrastructure, increasing investments in advanced medical technologies, and a rising prevalence of cardiovascular and respiratory conditions. In addition, the growing awareness and adoption of ECMO systems in emerging markets across Asia-Pacific further drives market growth.
Competition Analysis
Key players such as Abbott Laboratories and Medtronic plc have adopted product approval, partnership, expansion, and collaboration as key developmental strategies to improve the product portfolio of the extracorporeal membrane oxygenation market. For instance, in April 2023, Abbott announced two new clearances from the U.S. Food and Drug Administration (FDA) for the company's industry-leading life support system. With the new indication, the CentriMag Blood Pump for use with the CentriMag System, is now cleared for longer-term use in adults when extracorporeal membrane oxygenation (ECMO) a type of life support for people whose heart and lungs are not working is critical to saving their life.
Recent Developments in Extracorporeal Membrane Oxygenation Industry
- In January 2025, CytoSorbents Corporation, a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification announced the opening of a new regional sales subsidiary in Dubai, United Arab Emirates (UAE). The new subsidiary provides a gateway into the Middle East and Africa regions with increasing demand for advanced medical technologies and high-quality therapies in critical care and cardiac surgery.
- In September 2024, Medtronic plc, the global leader in medical technology announced the launch of a new ECMO system called VitalFlow, which is a configurable one-system ECMO solution, built on simplicity and performance. The VitalFlow ECMO System bridges the gap between bedside care and intra-hospital transport, offering physicians and clinicians an easier, smarter ECMO experience.
- In April 2022, Getinge partners with IFC to help increase access to medical equipment across Africa. Getinge is now joining the International Finance Corporation’s (IFC) initiative to help health care providers in East and West Africa get better access to life-saving equipment.
- In January 2021, CytoSorbents Corporation announced that the Korean Ministry of Food and Drug Safety (KMFDS) approved CytoSorb for all equivalent European Union (E.U.) approved indications, including the reduction of cytokine storm, the reduction of bilirubin in liver disease, the reduction of myoglobin in trauma, and the removal of ticagrelor and rivaroxaban during urgent or emergent cardiothoracic surgery.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the extracorporeal membrane oxygenation market analysis from 2023 to 2035 to identify the prevailing extracorporeal membrane oxygenation market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the extracorporeal membrane oxygenation market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global extracorporeal membrane oxygenation market trends, key players, market segments, application areas, and market growth strategies.
Extracorporeal Membrane Oxygenation Market Report Highlights
| Aspects | Details |
 Market Size By 2035 | USD 952.2 million |
 Growth Rate | CAGR of 5% |
 Forecast period | 2023 - 2035 |
 Report Pages | 403 |
 By Modulation |
|
 By Application |
|
 By Patient Type |
|
 By Component |
|
 By Region |
|
 Key Market Players | LivaNova PLC, Chalice Medical Ltd., Eurosets, Fresenius SE & Co. KGaA, CytoSorbents Corporation, MicroPort Scientific Corporation, Terumo Corporation, Abbott Laboratories, Getinge, Medtronic plc |
Analyst Review
This section provides various opinions of top-level CXOs in the extracorporeal membrane oxygenation market. According to the insights of CXOs, increase in demand for extracorporeal membrane oxygenation is driven by rise in prevalence of respiratory and cardiac disorders, advancements in ECMO technology, and improved survival rates in critical care patients.
CXOs further added that growing adoption of ECMO in intensive care units, along with expanding applications in pediatric and neonatal care, further fuels the market growth. In addition, increase in healthcare investments, improved accessibility to ECMO centers, and favorable government initiatives are expected to accelerate market expansion in the coming years.
Furthermore, North America is expected to witness the largest growth, in terms of revenue, owing to presence of advanced healthcare infrastructure, high adoption of ECMO in critical care settings, and increase in prevalence of respiratory and cardiac disorders. The region benefits from strong government support, favorable reimbursement policies, and significant investments in ECMO research and development. However, Asia-Pacific is expected to register the highest CAGR during the forecast period, owing to rise in prevalence of respiratory and cardiac diseases, improving healthcare infrastructure, and increasing investments in critical care in the region.
The total market value of extracorporeal membrane oxygenation market was $527.52 million in 2023.
The forecast period for extracorporeal membrane oxygenation market is 2024 to 2035.
The base year is 2023 in extracorporeal membrane oxygenation market.
The market value of extracorporeal membrane oxygenation market is projected to reach $952.22 million by 2035.
Top companies such as Getinge, Medtronic plc , LivaNova PLC, Fresenius SE & Co. KGaA, and Terumo Corporation held a high market position in 2023.
The growth of the extracorporeal membrane oxygenation (ECMO) market is driven by the rising prevalence of respiratory and cardiac disorders, advancements in ECMO technology, and increasing healthcare investments.
The oxygenator segment holds the largest market share in 2023. This is attributed to the essential role of oxygenators in the ECMO procedure, as they are responsible for oxygenating the blood and removing carbon dioxide, making them a critical component of ECMO systems.
Extracorporeal Membrane Oxygenation (ECMO) is a medical procedure used to provide temporary life support for patients with severe heart and lung failure.
Loading Table Of Content...
Loading Research Methodology...
